Dissolve Strips ™ (sublingual cannabis wafers) Now Out there to Aurora’s Canadian Healthcare Individuals
NYSE | TSX: ACB OTC: CTTH
EDMONTON and HAMILTON, ON, Oct. eight, 2019 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (NYSE | TSX: ACB), the Canadian organization defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC | CTTH) announced currently the productive commercialization of CTT’s cannabinoid-infused sublingual wafers. The new cannabis item line, a 1st of its sort, has been launched by Aurora in the Canadian health-related cannabis market place below the brand name “Dissolve Strips™”.
Aurora has an ownership interest in CTT of roughly 9%, with a warrant enabling it to raise its stake to 42.five%, and access to CTT’s sublingual cannabis wafers drug delivery technologies, which is patent protected or patent pending in various jurisdictions.
Terry Booth, CEO of Aurora stated:
“Aurora’s Dissolve Strips™ provide exceptional benefits more than other ingestible goods due to their ease of administration, discrete nature and correct dosage, that offers additional speedy bioavailability of cannabinoids by means of sublingual use. This adds but yet another revolutionary providing to our developing portfolio of higher high-quality, health-related goods that we supply our patient base, and is testament to our business top potential to perform with technologies partners and regulators to bring new kind things to market place quickly.”
CTT’s CEO Cam Birge, added:
“The item launch with Aurora of the Dissolve Strips™ is a big milestone for us that marks the transition of CTT from a technologies improvement phase to a income producing phase. This is the culmination of years of tough perform by our founder Dr. Modi and the whole CTT and Aurora item improvement teams. We are quite proud of this co-achievement and congratulate Aurora for the considerable efforts and item enhancements to bring Dissolve Strips™ (sublingual cannabis wafers) to the cannabis market place. Our sights, having said that, are set significantly greater. The subsequent stage in our improvement will be the launch of a broader portfolio of exceptional goods on a international scale. We have been operating towards this, and I appear forward to reporting on our progress in the coming quarters.”
Orally Dissolvable Thin Film (“ODF”) Wafers (“wafers” or “sublinguals”) are a proprietary drug delivery mechanism in the kind of paper-thin polymer films employed as carriers for pharmaceutical agents that have the following added benefits:
- ODF Wafer is taken orally but does not demand water or swallowing
- ODF Wafers dissolve promptly in the oral cavity (five-15 seconds), with the active ingredient quickly absorbed and diffused for direct access to the bloodstream.
- The active ingredient, when absorbed, can bypass the liver’s 1st-pass impact, enhancing therapeutic outcomes and efficacy by means of enhanced bioavailability, and facilitates fantastic patient compliance.
- ODF Wafers are appropriate for a wide variety of individuals, which includes geriatric and pediatric individuals who encounter difficulty swallowing.
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 nations across 5 continents, Aurora is 1 of the world’s biggest and top cannabis businesses. Aurora is vertically integrated and horizontally diversified across each and every important segment of the worth chain, from facility engineering and style to cannabis breeding and genetics study, cannabis and hemp production, derivatives, higher worth-add item improvement, dwelling cultivation, wholesale and retail distribution.
Extremely differentiated from its peers, Aurora has established a uniquely sophisticated, constant and effective production technique, primarily based on objective-constructed facilities that integrate top-edge technologies across all processes, defined by substantial automation and customization, resulting in the enormous scale production of higher-high-quality constant item. Created to be replicable and scalable globally, our production facilities are made to generate cannabis at considerable scale, with higher high-quality, business-top yields, and low-per gram production fees. Every single of Aurora’s facilities is constructed to meet European Union Very good Manufacturing Practices (“EU GMP“) requirements. Certification has been granted to Aurora’s 1st production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European health-related cannabis distributor Aurora Deutschland. All Aurora facilities are made and constructed to the EU GMP normal.
In addition to the Company’s speedy organic development and robust execution on strategic M&A, which to date consists of 17 wholly owned subsidiary companies–
- Peloton Pharmaceutical
- Aurora Deutschland
- H2 Biopharma
- BC Northern Lights
- Larssen Greenhouses
- CanniMed Therapeutics
- HotHouse Consulting
- MED Colombia
- ICC Labs
- Chemi Pharmaceutical
Aurora is distinguished by its reputation as a companion and employer of selection in the international cannabis sector, getting invested in and established strategic partnerships with a variety of top innovators, which includes: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), Higher Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).
Aurora’s Typical Shares trade on the TSX and NYSE below the symbol “ACB”, and is a constituent of the S&P/TSX Composite Index.
For additional facts about Aurora, please pay a visit to our investor web page, investor.auroramj.com
About CTT Pharmaceutical
CTT’s principal asset is a exceptional and novel patented drug delivery technologies, an orally administered, quick dissolving thin film (the “Wafer”). This technologies platform will target each the human and veterinarian (pet) markets for remedy of a lot of ailments. The Organization believes that its Wafer technologies will be 1 of the 1st to achieve use in big markets such as discomfort management. A number of Canadian and U.S. patents shield the Oral Thin Film (Sublingual Cannabis Wafer) formulation.
CTT’s oral quick dissolving drug delivery systems consist of edible Wafers. These wafers dissolve devoid of water and inside a couple of seconds just after placement in the mouth. The majority of drugs administered applying our drug delivery technique mirror injections as:
- They have the potential to enter the bloodstream promptly
- They are handy and discreet
- And they can be administered anyplace
A quicker absorption price is accomplished for the reason that the mouth includes a quite thin mucosa and is exceptionally vascular.
There is no bitter taste, no smoke inhalation, much less degradation of medication (by bypassing the stomach). And most importantly, reduced dosage units are essential offered the efficacy of absorption. Patient compliance is also enhanced in particular with these who have a worry of choking or difficulty swallowing, and/or are pediatric, geriatric or incapacitated.
For additional facts, please pay a visit to our web page: www.cttpharmaceuticals.com
|Terry Booth, CEO||Cam Birge, CEO|
|Aurora Cannabis Inc.||CTT Pharmaceutical Holdings Inc.|
Supply Aurora Cannabis Inc.